Joseph Catanzaro
Stock Analyst at Piper Sandler
(0)
# 4352
Out of 5,325 analysts
120
Total ratings
33.33%
Success rate
-14.32%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CTMX CytomX Therapeutics | Maintains: Overweight | 4 3 | 0.74 | 237.84% | 4 | Apr 14, 2025 | |
IOVA Iovance Biotherapeut... | Maintains: Neutral | 8 6 | 3.25 | 84.62% | 10 | Feb 28, 2025 | |
SDGR Schrodinger | Maintains: Overweight | 50 45 | 25.73 | 74.89% | 3 | Feb 27, 2025 | |
MRUS Merus | Initiates Coverage On: Overweight | 84 | 42.86 | 95.99% | 1 | Feb 13, 2025 | |
GILD Gilead Sciences | Maintains: Overweight | 105 110 | 105.97 | 3.8% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 37 38 | 37.04 | 2.59% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 15 | 14.27 | 5.12% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 52 53 | 58.1 | -8.78% | 8 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 10 | 3.03 | 230.03% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 57 70 | 38.3 | 82.77% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 2 | 1.77 | 12.99% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 19 | 2 | 850% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 19 | 4.5 | 322.22% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 15 | 1.6 | 837.5% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 5 2 | 2.05 | -14.63% | 3 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 4 | 0.32 | 1071.88% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 5 | 2.77 | 71.48% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 36 | 26.76 | 34.53% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 40 | 7.53 | 431.21% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 15 | 7.99 | 87.73% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 35 35 | 11.82 | 196.11% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | 1 | 350% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 30 | 2 | 1400% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 1.55 | 1190.32% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 8 2 | 1.48 | 35.14% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 10 | 0.86 | 1062.79% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 1.5 | 1100% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 10 | 10.25 | -2.44% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 24 31 | 31.23 | -0.74% | 2 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 25 | 1.35 | 1751.85% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 58 | 58.7 | -1.19% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 2 | 2.74 | -36.13% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 20 | 23.17 | -13.68% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 11 | 11.17 | -1.52% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 90 70 | 23.01 | 204.22% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 2 | 0.67 | 123.88% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 10 | 0.38 | 2531.58% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 600 500 | 3.49 | 14226.65% | 1 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 35 | 4.07 | 759.95% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 60 | 1.21 | 4858.68% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 175 170 | 228.74 | -25.68% | 5 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 60 | n/a | n/a | 3 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | n/a | n/a | 2 | Jul 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 18 | 3.04 | 492.11% | 3 | Apr 7, 2020 |